Adalimumab is a medication used to treat various autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, and Crohn's disease. It belongs to a class of drugs called tumor necrosis factor (TNF) inhibitors, which help reduce inflammation and control the immune system's overactivity. Adalimumab is administered via injection and works by targeting TNF-alpha, a pro-inflammatory protein. Its therapeutic applications extend to managing symptoms, improving the quality of life for patients, and preventing disease progression in autoimmune disorders.
According to Data Bridge Market Research, the Global Adalimumab Market is accounted at USD 20,912.1 million in 2021 and is expected to reach USD 31,610.01 million by 2029. The market is expected to grow with a CAGR of 5.30% in the forecast period of 2022 to 2029.
“Increase in the incidence rate of autoimmune diseases boosts the market’s growth”
The adalimumab market is experiencing growth due to a notable increase in the incidence rate of autoimmune diseases. Autoimmune disorders, where the immune system mistakenly attacks healthy cells, have become more prevalent. Adalimumab, a biological medication, effectively manages these conditions by suppressing immune responses. As the global autoimmune disease burden rises, the demand for adalimumab and similar therapies grows, driving market expansion. This trend underscores the importance of advanced treatments in improving the quality of life for individuals affected by autoimmune diseases.
What restraints the growth of the global adalimumab market?
“Substantial manufacturing costs restraints the market’s growth”
The growth of the adalimumab market is constrained by the substantial manufacturing costs associated with this biologic drug. Adalimumab production involves complex biotechnological processes, stringent quality control, and compliance with regulatory standards, making it an expensive endeavor. These high manufacturing costs can result in elevated drug prices, limiting access for patients and healthcare systems.
Segmentation: Global Adalimumab Market
The global adalimumab market is segmented on the basis of drug class, type, indication, dosage form, dosage strength, drug type, route of administration, age group, end-users, and distribution channel.
- On the basis of drug class, the adalimumab market has been segmented into antirheumatics, TNF Alfa inhibitors, and others.
- On the basis of type, the adalimumab market has been segmented into biologics, biosimilars.
- On the basis of indication, the adalimumab market has been segmented into rheumatoid arthritis, ankylosing spondylitis, chronic plaque psoriasis, crohn's disease, ulcerative colitis, psoriatic arthritis, juvenile idiopathic arthritis, hidradenitis suppurativa, non-infectious intermediate, others.
- On the basis of dosage form, the adalimumab market has been segmented into Tablet, injection, solution, others.
- On the basis of dosage strength, the adalimumab market has been segmented into 40mg/0.4mlg, 80mg/0.8mlg, 20mg/0.2mlg, 10mg/0.1mlg, others.
- On the basis of drug type, the adalimumab market has been segmented into branded, generics.
- On the basis of route of administration, the adalimumab market has been segmented into oral, parenteral, and others.
- On the basis of age group, the adalimumab market has been segmented into pediatric, adult, geriatric.
- On the basis of end-users, the adalimumab market has been segmented into hospitals, specialty clinics, homecare, and others.
- On the basis of distribution channel, the adalimumab market has been segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others.
Regional Insights: North America dominates the Global Adalimumab Market
North America dominates the adalimumab market due to the increasing elderly population and a significant uptick in the prevalence of rheumatoid arthritis. Moreover, the expanding healthcare expenditure is poised to accelerate market growth in this area.
Asia-Pacific are expected to grow during the forecast period of 2022 to 2029 due to a growing emphasis on the development of generic and biosimilar products and an increasing elderly population. Additionally, investments in healthcare infrastructure are set to boost market growth in this region, addressing the healthcare needs of the aging demographic.
Recent Development
- In October 2021, The U.S. Food and Drug Administration (FDA) has granted approval for the first interchangeable biosimilar product to treat various inflammatory diseases. This milestone reflects the FDA's commitment to expanding treatment options for patients with serious medical conditions. Cyltezo is not only the first interchangeable monoclonal antibody but also the second biosimilar medicine to receive this authorization from the FDA.
To know more about the study visit https://www.databridgemarketresearch.com/es/reports/global-adalimumab-market
The Prominent Key Players Operating in the Global Adalimumab Market Include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France), Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Zydus Cadila (India)
- Biogen (U.S.)
- Fresenius Kabi AG (Germany)
- Boehringer Ingelheim International GmbH. (Germany)
- Amgen Inc. (U.S.)
- AbbVie Inc. (U.S.)
- Abbott (U.S.)
- CELLTRION INC. (South Korea)
- Samsung Bioepis (South Korea)
- Coherus BioSciences (U.S.)
- Innovent Biologics, Inc. (China)
- Hetero Biopharma Ltd. (India)
- Reliance Life Sciences (India)
Above are the key players covered in the report, to know about more and exhaustive list of global adalimumab market companies contact, https://www.databridgemarketresearch.com/es/contact
Research Methodology: Global Adalimumab Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
